Verastem Inc (VSTM)
NASDAQ:VSTM
Want to see VSTM full AI Analyst Report?
VSTM Stock Chart & Stats
$6.58
-$0.30(-4.59%)
At close: 4:00 PM EST
$6.58
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$3.55 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.56M
Market Cap
$362.04M
Enterprise Value$208.96M
Total Cash (Recent Filing)$181.68M
Total Debt (Recent Filing)$85.47M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 06, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding87,873,640
10 Day Avg. Volume2,445,218
30 Day Avg. Volume2,555,904
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue4.21
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda-1.09
Forecast
1Y Price Target
$16.00Price Target Upside143.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$103.49M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Healthy Gross MarginSustained ~60% TTM revenue growth alongside a ~52% gross margin signals product-market fit and scalable unit economics. Over 2–6 months this supports reinvestment in launches and trials, improving odds that incremental sales will meaningfully offset fixed SG&A and R&D if duration and refill metrics stabilize.
Commercial Launch Traction And Prescriber ExpansionGrowing prescriber base (>400), clear payer mix and patient-assistance uptake indicate durable commercial momentum. Management expects the LGSOC co-pack to fund commercial ops in H2 2026, which, if realized, reduces near-term funding dependency and validates the go-to-market model for this niche oncology franchise.
Pipeline Progression And Regulatory SupportProgression of VS-7375 into registration-directed Phase II trials plus Fast Track designation and first-patient dosing are durable de-riskers. They enhance the probability of a meaningful label and expedited review in KRAS G12D cancers, potentially creating a separate commercial revenue stream beyond the LGSOC co-pack.
Bears Say
Sustained Cash Burn And Limited RunwayPersistent operating and free cash outflows (~-$150.9M TTM) and a runway into H1 2027 create a durable financing overhang. Continued burn forces choices between dilutive funding, slowed development, or curtailed commercial investment, increasing execution risk for trials and launches across the next 2–6 months.
Very Large Operating And Net LossesExtreme operating and net losses reflect a cost structure where R&D and SG&A far exceed current product income. This structural unprofitability constrains free cash flow and elevates the need for ongoing funding, undermining long-term financial resilience unless revenue scales materially or costs are restructured.
Immature Commercial Metrics And Duration UncertaintyUncertain therapy duration and early discontinuations mean lifetime patient value and refill cadence are unproven. For a specialty oncology launch, durable revenue forecasting depends on stable duration/refill patterns; their immaturity raises the risk that current uptake may not translate into predictable, sustainable sales growth.
Verastem News
VSTM FAQ
What was Verastem Inc’s price range in the past 12 months?
Verastem Inc lowest stock price was $3.55 and its highest was $11.24 in the past 12 months.
What is Verastem Inc’s market cap?
Verastem Inc’s market cap is $362.04M.
When is Verastem Inc’s upcoming earnings report date?
Verastem Inc’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Verastem Inc’s earnings last quarter?
Verastem Inc released its earnings results on May 07, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.465 by $0.095.
Is Verastem Inc overvalued?
According to Wall Street analysts Verastem Inc’s price is currently Undervalued.
Does Verastem Inc pay dividends?
Verastem Inc does not currently pay dividends.
What is Verastem Inc’s EPS estimate?
Verastem Inc’s EPS estimate is -0.43.
How many shares outstanding does Verastem Inc have?
Verastem Inc has 87,873,640 shares outstanding.
What happened to Verastem Inc’s price movement after its last earnings report?
Verastem Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.465. Following the earnings report the stock price went down -13.604%.
Which hedge fund is a major shareholder of Verastem Inc?
Currently, no hedge funds are holding shares in VSTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (143.16% Upside)
$16.00 (143.16% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.61%
12-Months-Change
Fundamentals
Return on Equity
-486.41%
Trailing 12-Months
Asset Growth
72.98%
Trailing 12-Months
Company Description
Verastem Inc
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
VSTM Company Deck
VSTM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial and R&D progress with near-term operational and financial challenges. Highlights include steady product revenue growth ($18.7M in Q1; nearly $50M to date), expanding prescriber base (>400), improved PK/tolerability and progression of the 7375 Target-D program into Phase II registration-directed trials across PDAC, NSCLC and CRC (900 mg go-forward dose), and a cash position of $181.7M with runway into H1 2027. Lowlights include seasonal/access headwinds and early discontinuations reducing short-term refill volumes, high R&D and SG&A relative to current revenue leading to continued non-GAAP net losses (~$42.7M), immature duration/refill metrics, and practical dosing/formulation constraints at higher VS-7375 doses. Overall, positives (pipeline advancement, reimbursement and commercial actions, and encouraging VS-7375 data) are significant but offset by meaningful execution and funding risks in the near term.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$16.00
▲(143.16% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.52% Insiders
7.36% Mutual Funds
52.23% Other Institutional Investors
27.73% Public Companies and
Individual Investors